MIVT.OB~~Sector: Healthcare~~Industry: Medical Equipment & Supplies

[422fwhp]

Which way will she go...   

Financials out today:

http://finance.yahoo.com/q/is?s=mivt.ob

Good luck.

[runforthedoor]

   Some news out...this may catch interest into the studies final results said to be in a week.

http://www.pinksheets.com/quote/news.jsp?url=fis_story.asp%3Ftextpath%3DCOMTEX%5Cpz%5C2005%5C11%5C10%5C72244207.html%26clientid%3D168%26provider%3DPRIMEZONE_MEDIA_NETWORK%2C_INC.&symbol=MIVT

[gmarc66]

A.m news:

2005-11-15 03:30:01 
MIVT's Proprietary Stent Coating Technology Completes Major Long-Term Animal Study with Excellent Results; Six-Month Study Demonstrates Unparalleled Biocompatibility and Safety of MIVT HAp Coatings for Drug-Eluting Stent Applications 


VANCOUVER, British Columbia--(BUSINESS WIRE)--Nov. 15, 2005--
MIV Therapeutics, Inc. (OTCBB:MIVT) (FWB:MIV), a leading
developer of new generation biocompatible coatings and advanced drug
delivery systems, announced today that a pivotal long-term animal
study of its novel stent coating technology has been concluded, with
results that were unequivocally successful in demonstrating the
coating's excellent biocompatibility and safety.
The 6-month study, performed by Center for Research in
Cardiovascular Interventions of the Methodist Hospital Research
Institute, an independent research organization, indicated that MIVT's
Hydroxyapatite-based coatings were excellent candidates for advanced
drug-eluting stent coatings.
Dr. Greg L. Kaluza, MD, scientific director of the CRCI at the
Methodist Hospital Research Institute, was the lead investigator for
the study. Dr. Fred J. Clubb, Jr. of Texas Heart Institute served as a
study pathologist.
"The study's results are particularly encouraging for several
reasons," said Dr. Kaluza. "The polymeric stent coatings that are now
widely used are increasingly criticized as a suboptimal solution,
because many of them may elicit prolonged foreign body response and
foster platelet deposition which may in turn trigger in-stent
thrombosis," he said. "In contrast, the Hydroxyapatite coating we
studied is built entirely of a mineral native to the human body and as
such may have a long-term biocompatibility advantage."
The results of this recently completed study indicate this coating
may be safely used as a drug-eluting platform since it may be expected
from the present study that the Hydroxyapatite (HAp) coating will
remain inert in the arterial wall even long after the drug is
completely eluted. The well-known long-term neutral effects and
natural absorption of HAp coatings from orthopedic and dental implants
strongly reinforce this belief. The HAp coating with microporous
structure is expected to enable effective drug elution without ever
involving any polymer, a design concept that is currently viewed as
superior and the most attractive for drug-eluting stents."
"We now have a comprehensive set of data demonstrating that the
ultra-thin Hydroxyapatite coating with a potential for use in
non-polymeric and composite drug-eluting systems selected for this
study has excellent biocompatibility at all three studied time points,
up to as long as six months of observation," said Dr. Kaluza. "The
safety profile of the studied coating is exemplary and appears at
least on par with stainless steel stent surface, which remains a
benchmark whose biocompatibility has not been surpassed by any coating
to date."
Stents are devices implanted in the arteries to prop open the
blood vessels and maintain healthy blood flow to the heart and
throughout the body. MIVT has developed a next-generation line of
coatings based on a substance called Hydroxyapatite (HAp), to create
both passive and drug-eluting coatings designed to eliminate many of
the serious problems that are associated with current generations of
stent coatings.
"The study provided critical long-term data that reinforced our
preliminary research that has indicated the exceptional safety and
biocompatibility of our proprietary coating technologies," said Alan
Lindsay, CEO of MIVT. "The uncompromised biocompatibility stands
behind the potential of MIVT's HAp coating technologies and their
expected therapeutic advantages over the existing coatings and stent
technologies currently available to the biomedical industry."
The successful results of the animal study will enable MIVT to
plan future clinical trials to continue to advance its research and
product development programs for the multi-billion-dollar global stent
marketplace.
The study was conducted in a standard model of porcine coronary
arteries and utilized angiography, intravascular ultrasound and
histology to evaluate tissue response to HAp-coated stents in
comparison to identical stainless steel stents. The study was
performed in compliance with GLP (Good Laboratory Practice)
guidelines, CE-Mark and FDA requirements.
MIV Therapeutics is developing a diverse suite of HAp coating
formulas to enable the surface of stents and other implanted devices
to virtually mimic the natural state of structurally-sound 100%
biocompatible and bio-active tissue. Hydroxyapatite, unlike polymer
coatings, is naturally derived and found in such hard tissues and
bioceramic materials as human bone and teeth. Research has indicated
that MIVT's HAp coatings do not trigger the various adverse and
inflammatory reactions that are often associated with implantation of
polymer-coated stents and other foreign substances. HAp coatings are
also expected to reduce the risk of thrombogenic (blood clotting)
events attributable in some instances to polymer-coated stents. Some
of the most recent information presented at the TCT 2005 conference
estimated that thrombogenicity was identified in 20,000 cases of
implanted drug-eluting stents to-date, resulting in approximately
8,000 premature deaths.

[sebfr]

Hi,

I am very perplex with MIVT...We have good news but we can see a double top ! Fundamentaly, i can buy but technicaly i must to be very quiet ! Any ideas ??
For me i buy at 1.260
Stop loss at 1.100 (Very tigh)

News :
MIV Therapeutics Reports Highly Favorable Results in Preclinical Study of Innovative Stroke Prevention Device; Unique Implantable Anti-Stroke Device Progress on Track for Approval and Potential Commercialization
12/2/05       

VANCOUVER, British Columbia, Dec 02, 2005 (BUSINESS WIRE) --
MIV Therapeutics, Inc. (OTCBB: MIVT) (FWB: MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems, today announced highly favorable results demonstrated by preclinical studies of a unique filtration device designed to prevent strokes and other serious complications that can result from common cardiac procedures and other causes.

Called the Aortic Embolic Protection Device (AEPD), this implantable instrument is designed for implantation in the aorta -- the main artery providing blood supply to the brain. Once positioned, the AEPD functions as a deflector and filter to prevent migration of embolic particles and blood clots that can obstruct or block blood vessels supplying the brain, and thus prevent strokes that can result in brain damage, disability or death. Stroke is the third leading cause of death and the leading cause of severe disability in the world.

The study was designed to measure the device's safety and to confirm critical positioning and performance following implantation in the aorta. The results of the study performed on sheep under varying conditions are considered medically significant, and reinforce the device's potential as a viable preventive tool to fight strokes in cardiac patients.

MIVT's SagaX subsidiary is developing the AEPD stroke-prevention device.

"We're excited by this pivotal data from the ongoing preclinical studies being conducted on our novel stroke prevention device," said Dr. Dov Shimon, CEO of SagaX, and a renowned heart surgeon who invented the Company's stroke-preventing technology. "The results provide further validation of the life-saving potential of our proprietary devices for cardiac patients. Our technology is at the cutting-edge of scientific development in the prevention of cardio-embolic stroke, but the success of our stroke-prevention devices is rooted in their functional simplicity and ease of use."

The animal studies with the AEPD are being performed in the Animal Heart Catheterization Laboratory of the Hadassah University Hospital in Jerusalem, Israel, under the stewardship of Dr. Chaim Danenberg, a Senior Cardiologist, and Dr. Haim Lotan, the Chairman of the Department of Cardiology. These advanced exploratory studies pave the way to further full-scale animal and human trials and ultimately the FDA approval process and commercialization.

News sources have recently reported that the global market for implantable stroke prevention devices is expanding rapidly worldwide, and could grow into a potential $500 million to $1 billion market segment in the next few years. MIVT is committed to capitalizing on that marketplace opportunity for high growth revenue with its proprietary AEPD stroke prevention technology.

It is anticipated that following further successes in preclinical tests and clinical human trials, a first-generation device could be approved and successfully commercialized within relatively short period of time.

"We're extremely pleased with the very promising performance of the aortic protection device in all of the bench and animal model studies performed thus far and we are looking forward to further development and testing," said Alan Lindsay, CEO and president of MIV Therapeutics. "We believe the AEPD can help to reduce the threat of disabling or fatal strokes for cardiovascular patients and other patients in the high risk category for stroke."

About MIV Therapeutics

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Techicals :
Triangle is formed...
Double top

[setravis]

Press Release Source: MIV Therapeutics Inc.


MIV Therapeutics Premieres Research into Advanced Polymer-free Drug Delivery Systems at Leading Biomedical Conference
Thursday December 1, 3:30 am ET 
MIVT Premieres Revolutionary Drug Eluting System Based on its Proprietary Hydroxyapatite Coating Technologies


VANCOUVER, British Columbia--(BUSINESS WIRE)--Dec. 1, 2005--MIV Therapeutics, Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of new-generation biocompatible coatings and advanced drug delivery systems, and its strategic research partner, the University of British Columbia, presented their latest achievements in research and development of a revolutionary polymer-free coatings and drug delivery systems for vascular stents and other implantable medical devices, at the 2005 Materials & Processes for Medical Devices Conference, on November 16 in Boston, MA.


At the conference, MIVT revealed to industry and scientific professionals for the first time the latest research findings into its newest, revolutionary polymer-free drug eluting technology. Most importantly, the preliminary evaluation of these potentially breakthrough coatings confirmed their exceptional suitability for drug delivery purposes and delivered extremely promising drug eluting characteristics.

MIVT is developing advanced drug-eluting coatings for stents and other devices based on the use of porous calcium phosphate, a non-polymer alternative drug-carrying vehicle designed to eliminate problems associated with current polymer-based coatings now in use. Under the Company's research program, micro-thin films of calcium phosphates were deposited on a layer of ultra-thin Hydroxyapatite (HAp) as a vehicle for drug delivery purposes for a variety of implantable medical devices. MIVT already completed developing ultra-thin non-porous HAp coatings that have demonstrated exceptional biocompatibility and safety.

"The presentation of our newest coating and drug eluting technologies at the Boston conference gave us an opportunity for MIVT to make a decisive testimony of our achievements and capabilities before the industry's leading scientists and professionals," said Alan Lindsay, Chairman and CEO of MIVT. "The superb biocompatibility and safety of our proprietary coatings, complemented with the extremely promising characteristics of our drug delivery solutions, are designed to directly target the weaknesses of present drug delivery technologies used in cardiovascular stents and other medical devices. We are very pleased with preliminary evaluation results of these breakthrough technologies, which have generated considerable interest and appreciation throughout our industry."

Arc Rajtar, MIVT's Chief Technology Officer, assisted by Dr. Quanzu Yang, Ph.D., of the UBC's Department of Materials Engineering, delivered a comprehensive presentation of MIVT proprietary coating and drug delivery technologies titled, "Hydroxyapatite Coatings for Coronary Stents." The presentation highlighted the achievements of the MIVT and UBC research teams. The Hydroxyapatite-based technologies presented at the conference included sol-gel, electro-chemical and electrophoretic methods of deposition, which resulted in ultra-thin, calcium-phosphate bio-ceramic films. Long-term evaluation of MIVT's ultra-thin films used as a surface modification for metallic implants confirmed their exceptional biocompatibility and excellent safety during animal trials completed recently at the Methodist Hospital in Houston, TX.

MIVT's new line of ultra-thin and drug-eluting coatings for cardiovascular stents and other medical devices utilize material called Hydroxyapatite (HAp). MIVT is developing its coating systems to target the estimated $6 billion worldwide stent market. MIVT's coating solutions are also targeting the broader range of implantable medical devices, estimated to have the potential to grow to $100 billion or more in coming years.

"The Materials & Processes Conference gave us a unique audience to premiere our ultra-thin coating technologies for the professional community," said Mr. Rajtar. "The high-resolution electronic microscopy pictures of our polymer-free drug eluting coatings and the research results we presented were very well-received by our scientific peers and key industry representatives."

MIVT's R&D teams are continuing to accelerate the pace of work on the Company's breakthrough solutions. As a result of encouraging research findings, this portion of the Company's development program is approximately 6 months ahead of schedule, Mr. Rajtar added.

About MIV Therapeutics, Inc.

MIV Therapeutics Inc. is developing a next-generation line of advanced biocompatible coatings and drug delivery systems for cardiovascular stents and for application on broad range of implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated superior biocompatibility and excellent safety pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug eluting coatings currently in the stent market. The Company's drug eluting coatings are designed to suit broad range of implantable medical devices which are expected to benefit from a highly customizable drug release profile not offered by competitive solutions. MIVT's Collaborative Research Agreement (CRA) with the University of British Columbia is supported with research and development grants from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council - Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.



Contact:
MIV Therapeutics Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
E-mail: [email protected]
Web: http://www.mivtherapeutics.com/
or, for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
[email protected]
or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-342-1467
[email protected]

--------------------------------------------------------------------------------
Source: MIV Therapeutics Inc.

[setravis]

Possible trend reversal after bottoming around $1.14 on Monday.
Now @ +7.50%..........Volume @.......199,663


Technicals
Last Price Quote is:
20.33%above 13-day EMA
110.58%above 50-day EMA

[setravis]

Press Release Source: BiomedDiscoveries.com


MIV Therapeutics Spotlights Newest Clinical Results of Company's HAp-Based Stent Coating on BiomedDiscoveries.com
Thursday December 15, 3:30 am ET 
Chief Medical Officer Describes Positive Outcomes of Pivotal Study of Biocompatibility Coatings in Interview


LOS ANGELES--(BUSINESS WIRE)--Dec. 15, 2005--BiomedDiscoveries.com -- http://www.biomeddiscoveries.com, the online source for exclusive investor information in the biotechnology sector, today announced the online availability of a new Q&A style interview with Dr. Dov Shimon, Chief Medical Officer and Director of MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of new generation biocompatible coatings and advanced drug delivery systems.
   

In the interview, Dr. Shimon provides details of results from a pivotal long-term animal study of MIVT's proprietary Ultra-thin Hydroxyapatite (HAp) coating. In the recently completed study, a coronary stent coated with MIVT's HAp formulation was implanted in a porcine coronary artery. The coating was then studied over a six-month period to examine its biocompatibility, safety and efficacy in the animal's body.

The results showed the HAp coating to have, "superb compatibility and zero reactivity," Dr. Shimon said. "A number of variables were looked at in the study -- the exact measure of narrowing inside the stent reaction, beyond the stent, etc. -- and we're happy to report that there have been no adverse effects or reactions to the coating material."

He continued, "There are over one million patients every year who undergo implantation of coronary stents in the United States alone, to give an idea of how many patients' lives could be affected and improved by MIV Therapeutics' leadership in optimizing stent coating safety."

The study was performed at the Center for Research in Cardiovascular Interventions of the Methodist Hospital Research Institute, an independent research organization that is highly distinguished in the field.

Stents are coil-like metal devices that are used to prop open blocked arteries in cardiac patients. The results are expected to help pave the way to upcoming clinical trials with humans volunteers, and ultimately, to the Company's planned commercialization of this possible breakthrough technology in the fast-growing, multi-billion-dollar global stent marketplace.

MIVT has developed a portfolio of patented HAp coating technologies based on an organic substance found in human bone and teeth, in order to eliminate serious risks that are often associated with today's generation of polymer-based coatings on the market. The Q&A interview can be read free of charge by visiting http://www.biomeddiscoveries.com.

About MIV Therapeutics, Inc.

MIV Therapeutics, Inc. is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting application on cardiovascular stents and for application on a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed primarily to protect surrounding tissue from the chemical interaction with metal stents. The Company's unique ultra-thin coating has been derived from a biocompatible material called Hydroxyapatite (HAp) that during in-vivo animal trials demonstrated excellent safety and exceptional biocompatibility pursued by the science in the field of advanced implantable drug delivery systems. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth. It is widely used as a bone substitute material and for coating implantable fixation devices in orthopedic, dental and other applications. The Company's novel drug-eluting technologies based on Hydroxyapatite provide an attractive alternative solution to polymer-based drug-eluting coatings currently in the stent market. The Company's drug-eluting coating is designed to suit a broad range of implantable medical devices which may benefit from a highly customizable drug release profile. MIVT reached a Collaborative Research Agreement (CRA) with the University of British Columbia and supported a research and development grant from the Natural Sciences and Engineering Research Council of Canada (NSERC) in 2002 for the development of Hydroxyapatite as a drug-eluting coating. In December 2004 MIVT received a Government grant for the research program titled "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents" under the National Research Council -- Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship the Company will progress to the development stage, which is expected to finalize the drug-eluting research and development Program. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

About BiomedDiscoveries.com

BiomedDiscoveries.com provides exclusive commentary, research, interviews and other information about the smallcap investment marketplace. BiomedDiscoveries.com strives to provide investors with information and research-based data regarding important individual companies and overall marketplace trends. Resources available on BiomedDiscoveries.com include audio interviews with corporate leaders and respected commentators, as well as technical white papers and other forms of market and investment analysis. It is located at http://www.biomeddiscoveries.com.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Compensation and Other Disclosures

BiomedDiscoveries.com is a wholly owned subsidiary of Trilogy Capital Partners, Inc. Trilogy Capital Partners provides investor relations services to public companies. The companies presented by BiomedDiscoveries.com are usually clients of Trilogy Capital Partners and compensate Trilogy Capital Partners for these services, including cash compensation and equity securities. In addition, Trilogy Capital Partners and its affiliates may own securities of the presenting companies, and may from time to time purchase and sell securities of these companies in the open market or in private transactions. Trilogy receives compensation from MIV Therapeutics of $10,000 per month through November 2005 and thereafter for so long as Trilogy is retained to provide investor relations services. Trilogy has non-transferable warrants from this company to purchase 2,720,000 shares of common stock for $0.26 per share and expiring in November 2007, provided that Trilogy may not exercise the warrants to the extent that following such exercise Trilogy would beneficially own 5% or more or the outstanding common stock of this company.



Contact:
BiomedDiscoveries.com
Astra Thomas, 800-592-6061

--------------------------------------------------------------------------------
Source: BiomedDiscoveries.com

[setravis]

Possible trend reversal after bottoming around $1.14 on Monday.
Now @ +7.50%..........Volume @.......199,663


Technicals
Last Price Quote is:
20.33%above 13-day EMA
110.58%above 50-day EMA

Has formed a Symmetrical Triangle (continuation) Pattern
Looking like it wants to Breakout....soon !

[setravis]

Maybe we have something cooking again

[422fwhp]

Came back to the 61.8% but nonetheless is above it now.  RSI is iffy.  Opinions?

[422fwhp]

...news from Mar. 2:

http://biz.yahoo.com/bw/060302/20060302005044.html?.v=1

MIVT Invited to Lecture on Proprietary Biocompatible Coatings for Implanted Medical Devices and Drug Delivery Systems
Thursday March 2, 3:30 am ET 
Company Scientist Presents Data on Next Generation Coatings and Applications for Localized Treatment of Diseases


VANCOUVER, British Columbia--(BUSINESS WIRE)--March 2, 2006--MIV Therapeutics Inc. (OTCBB:MIVT - News; FWB:MIV), a leading developer of next generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, announced that one of its chief scientists presented a lecture at the University of Washington detailing recent research findings on the company's innovative drug delivery systems designed to improve the performance of currently available cardiovascular stents and other implantable medical devices and the targeted treatment of cardiovascular and other chronic diseases.


Prof. Tom Troczynski, VP of Coatings at MIVT presented the lecture entitled "Advances in Hydroxyapatite-Based Bio-Ceramic and Composite Thin Films for Implant Surface Modification and Drug Delivery," to the Faculty of the Department of Materials Science and Engineering at the University of Washington, in Seattle WA, on Feb. 13, 2006.

Prof. Troczynski's presentation focused on the science of wet chemical technologies behind the novel ultra-thin and micro-thin HAp-based bio-ceramic coatings and drug delivery systems that MIVT has developed for cardiovascular stents, other implantable medical devices and localized drug delivery for the treatment of chronic diseases.

MIVT has developed a family of novel HAp-based device coatings and drug delivery systems that provide the highest level of performance, while avoiding or counter-measuring serious medical and biocompatibility problems demonstrated by the coating technologies of current drug delivery systems. A comprehensive range of animal trials by MIVT has confirmed research that MIVT's biocompatible HAp coatings do not trigger the adverse bodily reactions such as restinosis, thrombosis (dangerous blood clotting) and biocompatibility problems that are causing some concern in the medical implantable device marketplace.

Initial studies have confirmed that the HAp polymer-free coatings can be successfully used for the targeted delivery of anti-inflammatory and other drugs for orthopedic and cardiovascular applications. The delivery of localized therapies to other organs of the body is also under intense investigation and is expected to deliver breakthrough solutions for the treatment of many chronic diseases including Cancer. MIVT believes that the future treatment of diseases will rely heavily on the novel HAp-based drug delivery systems and novel polymer-free drug delivery systems developed by the company.

Prof. Troczynski also reviewed the HAp-based products' demonstrated ability to maintain structural and functional integrity and performance through deployment in the body and during long-term use following implantation.

The Department of Materials Science and Engineering at the University of Washington is recognized as one of the world's top providers of education in the materials field. "The direct interaction of faculty and research staff from different universities and scientific institutions is a powerful mechanism for the advancement of our fundamental and applied knowledge of complex biomaterials systems," said Prof. Troczynski. "The proximity of the Department of Materials Science and Engineering to our laboratories at UBC in Vancouver makes such contacts particularly attractive to both organizations. We have hosted the MSE researchers and faculty in the past and we will benefit from this continuous learning process as we develop new applications for our coating and drug delivery technologies in the important cardiovascular and orthopedic fields."
-----------------------------------

Maybe the lecture stirred some interest?

I had nibbled some at the bottom bollinger...now wondering if I should take profits?

Increasing volume, not overbought yet, resistance at $1.12 ?

Bueller?   

laterz...Jody

[la-onda]

time for reentering?

MIV Therapeutics Subsidiary, SagaX Inc., Accelerates Development of Surgical Stroke Prevention Device Towards Commercialization
Friday March 10, 4:01 pm ET
First Generation Device Could be Ready for Clinical Use Within 14 Months

VANCOUVER, British Columbia--(BUSINESS WIRE)--March 10, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV) a leading developer of next generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, has announced that it has accelerated development of a novel stroke-preventing implantable device for surgical patients, and may have the device ready for clinical use within 14 months, subject to regulatory approval.

The Aortic Embolic Protection Device (AEPD) is being developed by MIVT's wholly owned subsidiary, SagaX Inc., located in Herzlyia, Israel. SagaX is a developer of advanced biomedical technology, including the embolic protection devices for the prevention of strokes. MIVT recently announced the strengthening of the SagaX research and development program with the appointments of four new key executives and scientists.

The AEPD under development at SagaX is a unique and proprietary filter/deflector device designed specifically to prevent cardioembolic stroke following heart surgery. It works by diverting particles in the bloodstream that might otherwise reach the brain and cause strokes that can cause irreversible damage to the delicate tissue of the brain. The AEPD device is designed for easy insertion and positioning in patients by surgeons during the operation, and can be removed at the end of the procedure.

SagaX Inc. is also developing further generations of anti-embolic devices to protect the brain, for applications including trans-catheter procedures and for patients with high risk for cardioembolic stroke, such as those that have had a previous stroke, rhythm disturbance or received a prosthetic valve. The AEPD and similar devices could become commonplace in the near future, enhancing the success of cardiac procedures, and more importantly, improving the individual patient's health, longevity and quality of life.

The highly innovative SagaX AEPD device is designed to significantly reduce stroke occurrence, following heart operations. The occurrence of significant cardioembolic stroke following surgery is estimated between one and four percent, although minor neurological deficit is seen in as much as 15% to 30% of surgical patients.

Stroke is the third leading cause of death, and the leading cause of disability. According to a recent publication of the American Heart Association (AHA), each year about 700,000 Americans experience a new or recurrent stroke. About 500,000 of these are first attacks, and 200,000 are recurrent attacks. It is also stated that the estimated direct and indirect cost of stroke in the US alone for 2006 is $57.9 billion.

On his recent trip to the facilities in Israel, Alan Lindsay, Chairman and CEO of MIVT, said: "I am extremely impressed with the rapid development of this life saving technology. I am especially pleased with the quality and dedication of our talented team in Israel."

Recent reports indicate that the global market for implantable stroke prevention devices is expanding rapidly worldwide, and will grow into a $500 million to $1 billion market segment in the next few years.

[setravis]

Back above the 13/50/200-dma

Volume: 463,460
Avg Vol (3m): 361,136

Technicals
Percentage Gainer

Last Price Quote is:
16.23%above 13-day EMA
16.22%above 50-day EMA

[rdemp52572]

I was doing a little reading over the weekend and came across this possible gem (MIVT) and just bought some this morning:

MIV Therapeutics (MIVT) is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage.

http://biz.yahoo.com/bw/060707/20060707005403.html?.v=1

Buy some before Boston Scientific or J&J want to take them over!

[setravis]

Press Release Source: MIV Therapeutics


MIV Therapeutics to Hold Investor Conference Call at 12:00 PM Eastern Tuesday, July 11
Monday July 10, 1:42 pm ET 
Company President Mark Landy to Update Investors on Key Data Validating MIVT's Program to Create Safer, Better Coronary Stents


VANCOUVER, British Columbia--(BUSINESS WIRE)--July 10, 2006--MIV Therapeutics (OTCBB:MIVT - News; FWB:MIV), a leading developer of next-generation biocompatible coatings and advanced drug delivery systems for cardiovascular stents and other implantable medical devices, will host an investor conference call tomorrow, Tuesday, July 11, 2006, at 12:00 PM Eastern, to discuss a growing body of evidence that validates the Company's innovative program to make a safer generation of coronary stents based on its unique, bio-friendly coating technologies.


During the call, Company President Dr. Mark Landy will discuss reports published in both scientific journals and the mainstream media that further validates the medical and marketplace demand for improved stent coatings.

Stents are used to prop open coronary arteries that have been narrowed as a result of vascular disease; MIVT has developed and is testing for commercialization a new generation of stents with proprietary coating based on an organic substance called hydroxyapatite (HAp), which can be found in human bone and teeth. MIVT's unique HAp-based stent coatings are specifically designed to prevent the adverse negative reactions to existing stent implants that themselves can cause blood clots, heart attacks and other serious complications.

Dr. Landy will discuss some of the important research about the potential dangers, including the risk of death, posed by current generations of coronary stents. They will contrast those reports with an increasing body of scientific data and new independent studies that demonstrates the superior safety potential of MIVT's unique stent coating solutions. Following their presentation, Dr. Landy will respond to callers' questions.

"We believe MIV Therapeutics' unique HAp-based coating solutions will provide a crucial and safe alternative for patients," said Dr. Landy. "We look forward to discussing the most recent research surrounding and confirming HAp safety studies, as we continue to execute our strategy to create a new generation of improved technologies within the multi-billion-dollar stent industry."

To participate in the conference call, investors within the United States may dial (888) 428-4478 in advance of the call. When prompted, please tell the operator that you would like to connect to the MIV Therapeutics conference call. International callers can dial (612) 332-0228. Participation in the conference call is free of charge to all interested investors. If you are unable to participate in the call in real time, a transcript of the conference call will be archived for future replay at http://www.trilogy-capital.com/tcp/html/mivt.htm.

About MIV Therapeutics Inc.

MIV Therapeutics is developing a next-generation line of advanced biocompatible coatings for passive and drug-eluting applications on cardiovascular stents and a broad range of other implantable medical devices. The Company's ultra-thin coating formulation is designed to protect surrounding tissue from potentially harmful interactions with bare metallic stents. The Company's unique ultra-thin coating platform is derived from an organic material called hydroxyapatite (HAp) which has demonstrated excellent safety and biocompatibility in vivo animal studies. Hydroxyapatite is a bioactive porous material that makes up the bone mineral and matrix of teeth and is widely used today as a bone substitute material and for coatings on implantable fixation devices in orthopedic, dental and other applications. The Company's novel polymer-free drug eluting technologies based on Hydroxyapatite could also provide an attractive alternative to current polymer-based drug eluting coatings on the stent market, which have been associated with undesirable medical effects. The Company's drug eluting coatings are additionally designed to suit a broad range of implantable medical devices that could benefit from highly customizable drug release profiles. MIVT has a Collaborative Research Agreement (CRA) with the University of British Columbia and has received Government grant for its research program on the "Development of Novel Drug Eluting Composite Coatings for Cardiovascular Stents," under the National Research Council-Industrial Research Assistance Program (NRC-IRAP). Under this sponsorship, the Company is expected to complete its drug-eluting research and development program and to reach product commercialization stage. For more information, please visit http://www.trilogy-capital.com/tcp/mivt/website.html. To read or download MIV Therapeutics' Investor Fact Sheet, visit http://www.trilogy-capital.com/tcp/mivt/factsheet.html. To obtain daily and historical Company stock quote data, and recent Company news releases, visit http://www.trilogy-capital.com/tcp/html/mivt.htm. MIVT is traded on the Frankfurt, Germany, stock exchange under the symbol MIV.

Forward-Looking Statements

Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Such statements are indicated by words or phrases such as "believe," "will," "breakthrough," "significant," "indicated," "feel," "revolutionary," "should," "ideal," "extremely" and "excited." These statements are made under "Safe Harbor" provisions of the Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See the Company's filings with the Securities and Exchange Commission including, without limitation, the Company's recent Form 10-K and Form 10-Qs, which identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.

Contact:
MIV Therapeutics Inc.
Investor Relations, 604-301-9545 x14
Toll-free: 800-221-5108
Fax: 604-301-9546
E-mail: [email protected]
Web: http://www.mivtherapeutics.com/
or, for Product Inquiries and Business Opportunities:
Arc Rajtar, 604-301-9545 Ext. 22
[email protected]
  or
Trilogy Capital Partners
Paul Karon, Toll-free: 800-592-6067
[email protected]

--------------------------------------------------------------------------------
Source: MIV Therapeutics